Name: Mal-VC-PAB-PNP
Brand: BOC Sciences
Rating: 5 (1 reviews)

Synonyms

Mal-Val-Cit-PAB-PNP; MC (C3)-Val-Cit-PAB-PNP

IUPAC Name

[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate

Canonical SMILES

CC(C)C(C(=O)NC(CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)COC(=O)OC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)CCN3C(=O)C=CC3=O

InChI

InChI=1S/C32H37N7O11/c1-19(2)28(37-25(40)15-17-38-26(41)13-14-27(38)42)30(44)36-24(4-3-16-34-31(33)45)29(43)35-21-7-5-20(6-8-21)18-49-32(46)50-23-11-9-22(10-12-23)39(47)48/h5-14,19,24,28H,3-4,15-18H2,1-2H3,(H,35,43)(H,36,44)(H,37,40)(H3,33,34,45)/t24-,28-/m0/s1

InChIKey

WZLBRPXGGXMQRU-CUBQBAPOSA-N

Appearance

White to Off-white Solid

Mal-VC-PAB-PNP is a conjugate widely used in the development of targeted cancer therapies, particularly in antibody-drug conjugates (ADCs). The maleimide (Mal) group allows for the selective conjugation of the compound to thiol-containing biomolecules, such as antibodies or peptides, enabling targeted delivery to cancer cells. The VC (Val-Cit) linker is a cleavable bond that ensures the controlled release of the cytotoxic payload, PNP (Pyrrolobenzodiazepine), within the target cells. PNP is a potent DNA-crosslinking agent that disrupts the integrity of the DNA helix, leading to cell death. The PAB (para-amino benzoic acid) spacer enhances the stability and solubility of the conjugate, optimizing its pharmacokinetics and improving its therapeutic efficacy. This makes Mal-VC-PAB-PNP a promising candidate for precise drug delivery in oncology.

One of the primary applications of Mal-VC-PAB-PNP is in the creation of targeted antibody-drug conjugates for cancer therapy. By linking PNP to an antibody via the maleimide group, this conjugate allows for selective delivery of the potent cytotoxic agent to cancer cells that express specific tumor markers. The VC linker ensures that PNP is only released after internalization by the target cell, minimizing off-target effects. Upon release, PNP binds to DNA and forms covalent crosslinks, preventing DNA replication and transcription, leading to cell cycle arrest and apoptosis. This targeted mechanism enhances the anti-tumor efficacy of PNP while reducing systemic toxicity, a key advantage in cancer therapy.

In addition to ADC development, Mal-VC-PAB-PNP can be used in drug resistance studies and the development of new therapeutic strategies. Researchers can utilize this conjugate to study how cancer cells develop resistance to chemotherapy and explore ways to overcome this resistance. By modifying the linker or the payload, scientists can test variations that might improve drug delivery or circumvent resistance mechanisms. This could lead to more effective treatments for resistant cancer strains and facilitate the design of next-generation ADCs with improved therapeutic outcomes.

Mal-VC-PAB-PNP also has potential applications in other fields of targeted therapy beyond oncology. The flexibility of the linker and the targeting group allows for the modification of this conjugate to suit the treatment of various diseases. For example, Mal-VC-PAB-PNP could be adapted for use in targeting infectious diseases or autoimmune disorders by linking the compound to antibodies or peptides that specifically bind to pathogens or disease-associated markers. This approach could broaden the use of PNP-based conjugates in non-cancerous therapeutic areas, opening up new avenues for research and clinical applications.